EGFR and gastric cancer: In addition, ECM1-mediated integrin β4 promotes EMT and glucose metabolism via SOX2/HIF-1α signaling in gastric cancer [117] and modulates epidermal growth factor receptor (EGFR) signaling to induce gefitinib chemoresistance [118].